Ion-Forming Channel Peptides for Treatment of Disease
Reference Number: 00-19
Inventors: John Tomich, Takeo Iwamoto, James R. Broughman, and Bruce D. Schultz
Kansas State University researchers have discovered a potential treatment of disease derived from sequence variants of the channel-forming peptides C-K4-M2GlyR and N-K4-M2GlyR. These sequences possess superior potency compared to those previously patented, and can be used to design more stable, higher-potency treatments for cystic fibrosis. Additionally, properties of certain sequences suggest that this new class of high-potency, channel-forming peptides may be useful in treating stroke, epilepsy, and cancer.
In the past, channel-forming peptides have not been used in the treatment of any disease. These newly derived channel forming-peptides provide a potential treatment for cystic fibrosis by producing improved anion-selective channels in the apical membrane of epithelial cells.
In addition to providing tenfold potency compared to previously patented sequences, many of these new sequences offer additional potential; for example, one exhibits a unique cell-killing capability that may be used to treat cancer, and another can be effective after being truncated, reducing the cost of using it in a drug. These factors lead to the potential for not only a profitable treatment for cystic fibrosis, but also for other diseases.
- Approximately 10 times as powerful as previously patented sequences
- Increased potency results in fewer peptides required to produce a high-conductance pathway
- Demonstrates potential for the treatment of cancer, stroke, epilepsy, and other conditions
- N-K4 sequences can be truncated to reduce the cost of synthesis and purification
- Production of anion-selective, channel-forming drugs for cystic fibrosis treatment
- May be used to develop new drugs to fight cancer and prevent stroke
- U.S. patent #8,163,870 issued on April 24, 2012.
Kansas State University Research Foundation seeks to have discussions with companies that are interested in licensing and/or research collaborations.
Interested parties should contact:
Kansas State University Institute for Commercialization (KSU-IC)
2005 Research Park Circle Manhattan, KS 66502
Tel: 785-532-3900 Fax: 785-532-3909